Background
Cancer cachexia is a complex, multifactorial syndrome characterized by a progressive loss of skeletal muscle mass with or without loss of fat mass that cannot be fully reversed by conventional nutritional support [
1]. Cachexia occurs in 50 to 80% of advanced cancer patients and is associated with decreased mobility [
2], reduced response to chemotherapy [
3], and is estimated to directly account for more than 20% of cancer-related deaths [
2]. There are no established therapies for cancer cachexia; accordingly, identification and testing of effective interventions are of major clinical importance in this at-risk population.
Cancer cachexia involves not only the loss of skeletal muscle, but also results in pathologic alterations within the heart [
4,
5]. The first report linking tumor burden and cardiac atrophy was first published in 1904 [
6], and was extensively outlined using autopsies by Hellerstein and Santlago-Stevenson in 1950 [
7]. More recent preclinical findings indicate that cardiac muscle loss occurs to a similar degree as in skeletal muscles, with concomitant impairment in systolic and diastolic function [
8,
9]. Collectively, the global nature of cachexia portends the requirement for multifactorial treatment strategies with the capacity to augment or reverse whole-organism atrophy.
Testosterone therapy has been used in patients exposed to atrophic stimuli [
10] to increase muscle strength and bone mineral density [
11,
12]. The heart is also a target organ for steroids; there are receptors with a high affinity for testosterone in cardiomyocytes [
13], suggesting that testosterone supplementation may also improve cardiac morphology and function. In support, a meta-analysis of randomized placebo-controlled studies found that testosterone administered to patients with chronic heart failure reduced systemic vascular resistance and increased both cardiac output and overall exercise capacity [
14]. However, whether there are similar salutary cardiovascular effects of testosterone in patients with advanced cancers is not known. Accordingly, as an ancillary analysis of a randomized, placebo controlled trial investigating the efficacy of testosterone supplementation on body composition in men and women with advanced cancers [
15], we explored whether testosterone supplementation could prevent or reverse left ventricular (LV) atrophy and dysfunction.
Discussion
This is the first randomized trial to explore the potential efficacy of testosterone to augment / reverse cardiac morphology and function in patients with advanced cancers. The major new findings of this study were that compared with placebo, testosterone improved LV systolic function, as well as ventricular-vascular coupling. This may have important health implications for patients with cachexia given that this entity has no established evidence-based interventions that improve outcomes.
Changes in cardiac morphology and function may stem from the cancer itself and/or the cardiotoxic effects of cancer therapies [
19]. For instance, Springer et al. [
8] reported extensive loss of cardiomyocyte volume and replacement with fibrotic tissue among patients who died of pancreatic, lung, and colorectal cancer; however, a subset of patients with significant cancer-related weight loss and cachexia had reduced LV wall thickness and mass compared with cancer patients without cachexia. A reduction in LV mass following anthracycline-based chemotherapy has also consistently been reported [
20,
21] and is associated with major adverse cardiac events (cardiovascular death, appropriate implantable cardioverter-defibrillator therapy, or admission for decompensated HF) [
21]. Of note, average BMI of included patients was ~ 27 kg/m
2, and whether patients with cachexia were included was not reported [
20,
21]. The present study confirms and extends previous reports by including patients with advanced cancers, none of whom had been previously treated with cytotoxic therapy or radiotherapy. Collectively, these findings indicate that cardiac alterations in patients with advanced cancers is part of a complex, systemic issue that results in widespread muscle wasting. Accordingly, intervention strategies with multifactorial effects will be required to reverse whole-organism atrophy.
At least 19 studies have assessed the efficacy of pharmacological agents in clinical trials to manage cancer cachexia [
22]; however, few have explored the potential salutary effects on cardiac morphology and function. Testosterone therapy has been used in patients exposed to atrophic stimuli [
10] to increase muscle strength and bone mineral density [
11], and we previously reported that in patients with advanced cancer adjunct testosterone improved lean body mass and was associated with increased quality of life, and physical activity compared with placebo [
15]. Previous findings from non-oncology settings indicate that exogenous testosterone may also directly induce physiological cardiac myocyte hypertrophy [
23]. For instance, among men with type 1 diabetes, higher total testosterone was associated with higher LV mass and volume [
24], and Subramanya and colleagues [
25] recently reported that after a median of 9.1 years, higher free testosterone levels were independently associated with an increase in LV mass in women and men in the Multiethnic Study of Atherosclerosis. In RCTs, testosterone treatment improved cardiac biomarkers in patients with type II diabetes [
26], and reduced systemic vascular resistance and increased both cardiac output and overall exercise capacity in heart failure patients [
14]. Similar findings were observed here in patients with advanced cancers; compared with placebo, testosterone improved indices of LV function. In addition, patients with the lowest LV ejection fraction at baseline experienced the greatest improvement with testosterone, suggesting that testosterone may be an important intervention for patients with poor LV ejection fraction. Nevertheless, these findings should be interpreted with caution given the small sample size. Collectively, these findings indicate that testosterone supplementation may be an effective intervention to improve cardiac function; however, larger trials are needed to address whether testosterone is fully protective against cardiac atrophic remodeling in patients with advanced cancers.
The mechanisms underlying testosterone-induced cardioprotection are not fully known; however, may involve both cardiac and vascular systems. Cardiomyocytes contain receptors with a high affinity for testosterone [
13] and in vitro studies of nonhuman cardiac myocytes found that testosterone can decrease action potential duration (thereby altering repolarization) and peak shortening times [
27]. Testosterone is also an acute vasodilator [
28] and lowers blood pressure [
29]. Thus, understanding how the heart and systemic vasculature function independently as well as how they interact (termed ventricular-arterial coupling) is important when evaluating global cardiovascular function [
17]. In the present study we found that testosterone had beneficial effects on vascular parameters (e.g., Ea, SVR), which in turn, improved ventricular-vascular coupling compared to placebo-treated patients. Future studies evaluating the mechanistic underpinnings of the effects of testosterone on cardiac and peripheral vasculature in the cachectic setting are needed.
In current clinical practice, the discipline of cardio-oncology traditionally focuses on the detection and management of cancer treatment-induced reductions in cardiac function (i.e., LVEF), and/or development of overt heart failure [
30‐
32] and coronary artery disease [
33]. Intriguingly, based on conventional metrics, all patients in the current study have ‘normal’ cardiac function (e.g., LVEF > 55%). Nevertheless, there is burgeoning interest in detection of early and subclinical therapy-related cardiac consequences, including changes in cardiac size and ventricular-vascular coupling. Furthermore, techniques such as assessing the heart during exercise has provided novel prognostic information beyond traditional resting cardiac measures in patients with breast cancer [
34]. Collectively, these findings indicate that evaluating cardiac morphology and function in the cachectic setting, as well as evaluating other metrics such as cardiorespiratory fitness and cardiac function during exercise will be important in the design of future intervention trials. Given the systemic effects of cachexia, evaluation of multimodal approaches including nutritional support, pharmacological intervention, and exercise training will be important for this high-risk population.
A number of study limitations should be considered. First, the trial was designed to assess the effect of testosterone treatment on lean body mass, and changes in cardiac parameters were not predefined outcome measures. Second, our sample size was small. Trials with larger samples sizes are needed to definitively assess the efficacy of testosterone on cardiac morphology and function in advanced cancers. Third, our subject population was predominantly female, and although androgens stimulate skeletal muscle protein synthesis similarly between men and women [
35], potential sex differences in cardiac androgen receptor density [
36] and the mechanisms of response to testosterone treatment may limit the generalizability of our findings. For instance, following exercise training the development of LV hypertrophy and increase in cardiorespiratory fitness in females was markedly blunted compared with males [
37]; whether females have blunted response to testosterone compared to males should be addressed in future studies. Finally, to fully characterize the physiological importance of atrophic remodeling and potential efficacy of testosterone supplementation, there is a need to move beyond the study of global measures of LV function at rest. For example, reduced strain and strain rate revealed impaired myocardial function prior to LVEF decline [
38] in cancer patients treated with anthracycline-containing therapy. Thus, evaluation of cardiac and vascular function with advanced imaging techniques at rest [
39], as well as responses to a peak cardiopulmonary exercise test [
40], may provide important insight into characterizing the ‘cachectic heart’.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.